Commentary|Videos|July 31, 2024
The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL
Author(s)Mazyar Shadman, MD, MPH, Marc S. Hoffmann, MD
Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
3
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
4
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
5